Not only for caregivers: intranasal glucagon for severe hypoglycaemia in a simulation study.
Adolescents
Children
Hypoglycaemia
Intranasal glucagon
Simulation
Type 1 diabetes
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
19
06
2022
accepted:
27
07
2022
pubmed:
12
8
2022
medline:
1
10
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
To evaluate: (i) the propensity of paediatrics and emergency medicine residents to select different therapeutic options and (ii) the speed and administration success in a high-fidelity simulation of severe hypoglycaemia in a child with type 1 diabetes (T1DM). In this single-centre high-fidelity simulation study, 51 paediatrics or emergency medicine residents were exposed to a scenario of severe hypoglycaemia in a T1DM child attending an ambulatory setting, before and after a training on the preparation and administration of both injectable and IN glucagon. Time for drug delivery and its effectiveness were collected. Before training, 45.1% of participants chose to administer injectable glucagon, 43.1% intravenous glucose solution, 5.9% intranasal (IN) glucagon, and 5.9% took no action. Administration was successful in 74% of injectable glucagon, 33.3% intravenous glucose solution, and 22.7% IN glucagon. After training, 58.8% of participants chose IN and 41.2% injectable glucagon, with 100% of successful administrations for IN glucagon and 90.5% for injectable glucagon. Time to successful administration was shorter for IN than injectable glucagon (23 ± 10 vs. 38 ± 7 s, p < 0.0001). IN glucagon is an easy and effective option for severe hypoglycaemia treatment, with an almost zero possibility of failure provided that adequate training is imparted.
Identifiants
pubmed: 35951133
doi: 10.1007/s00592-022-01952-6
pii: 10.1007/s00592-022-01952-6
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Glucagon
9007-92-5
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1479-1484Informations de copyright
© 2022. Springer-Verlag Italia S.r.l., part of Springer Nature.
Références
Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, Maahs DM (2018) ISPAD Clinical practice consensus guidelines 2018: assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 19(Suppl 27):178–192. https://doi.org/10.1111/pedi.12698
doi: 10.1111/pedi.12698
pubmed: 29869358
Cherubini V, Rabbone I, Lombardo F, Mossetto G, Orsini Federici M, Nicolucci A (2019) Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes in the real-life, post-diabetes control and complications trial setting: a systematic review. Pediatr Diabetes 20(6):678–692. https://doi.org/10.1111/pedi.12876
doi: 10.1111/pedi.12876
pubmed: 31177592
Perantie DC, Wu J, Koller JM, Lim A, Warren SL, Black KJ, Sadler M, White NH, Hershey T (2007) Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care 30:2331–2337. https://doi.org/10.2337/dc07-0351
doi: 10.2337/dc07-0351
pubmed: 17575089
Rabinovich A, Priefer R (2021) Glucagon delivery - An overview of current and future devices. Diabetes Metab Syndr 15(4):102155. https://doi.org/10.1016/j.dsx.2021.05.028
doi: 10.1016/j.dsx.2021.05.028
pubmed: 34198107
La Sala L, Pontiroli AE (2021) New fast acting glucagon for recovery from hypoglycemia, a life-threatening situation: nasal powder and injected stable solutions. Int J Mol Sci 22(19):10643. https://doi.org/10.3390/ijms221910643
doi: 10.3390/ijms221910643
pubmed: 34638984
pmcid: 8508740
Thieu VT, Mitchell BD, Varnado OJ, Frier BM (2020) Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon. Diabetes Obes Metab 22:469–479. https://doi.org/10.1111/dom.13941
doi: 10.1111/dom.13941
pubmed: 31820562
pmcid: 7079012
Rabbone I, Missineo A, Zanetta S, Salzano G, Schiaffini R, Scaramuzza AE, Lombardo F (2021) Parent and patient knowledge of nasal glucagon use and efficacy in a large cohort of Italian children and adolescents with type 1 diabetes. Diabetes Obes Metab 23(8):2004–2005. https://doi.org/10.1111/dom.14398
doi: 10.1111/dom.14398
pubmed: 33830640
Singh-Franco D, Moreau C, Levin AD, Rosa D, Johnson M (2020) Efficacy and usability of intranasal glucagon for the management of hypoglycemia in patients with diabetes: a systematic review. Clin Ther 42(9):e177–e208. https://doi.org/10.1016/j.clinthera.2020.06.024
doi: 10.1016/j.clinthera.2020.06.024
pubmed: 32873417
Matsuhisa M, Takita Y, Nasu R, Nagai Y, Ohwaki K, Nagashima H (2020) Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: a phase 3 randomized crossover study. Diabetes Obes Metab 22:1167–1175. https://doi.org/10.1111/dom.14019
doi: 10.1111/dom.14019
pubmed: 32115879
pmcid: 7318639
Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L (2020) Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: a randomised, open-label, crossover study. Diabetes Ther 11:1591–1603. https://doi.org/10.1007/s13300-020-00845-7
doi: 10.1007/s13300-020-00845-7
pubmed: 32514794
pmcid: 7324463
Pontiroli AE, Tagliabue E (2020) Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis. Acta Diabetol 57:743–749. https://doi.org/10.1007/s00592-020-01483-y
doi: 10.1007/s00592-020-01483-y
pubmed: 32025860
Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo VC, Zhang S, Carballo D, Pradhan S, Piché CA, Guzman CB (2018) Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab 20(5):1316–1320. https://doi.org/10.1111/dom.13278
doi: 10.1111/dom.13278
pubmed: 29504662
pmcid: 5947579
Deeb LC, Dulude H, Guzman CB, Zhang S, Reiner BJ, Piché CA, Pradhan S, Zhang XM (2018) A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes 19(5):1007–1013. https://doi.org/10.1111/pedi.12668
doi: 10.1111/pedi.12668
pubmed: 29512902
Binotti M, Genoni G, Rizzollo S, De Luca M, Carenzo L, Monzani A, Ingrassia PL (2019) Simulation-based medical training for paediatric residents in Italy: a nationwide survey. BMC Med Educ 19(1):161. https://doi.org/10.1186/s12909-019-1581-3
doi: 10.1186/s12909-019-1581-3
pubmed: 31113417
pmcid: 6529987
Settles JA, Gerety GF, Spaepen E, Suico JG, Child CJ (2020) Nasal glucagon delivery is more successful than injectable delivery: a simulated severe hypoglycemia rescue. Endocr Pract 26(4):407–415. https://doi.org/10.4158/EP-2019-0502
doi: 10.4158/EP-2019-0502
pubmed: 32293921
Yale JF, Dulude H, Egeth M, Piché CA, Lafontaine M, Carballo D, Margolies R, Dissinger E, Shames AR, Kaplowitz N, Zhang MX, Zhang S, Guzman CB (2017) Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther 19(7):423–432. https://doi.org/10.1089/dia.2016.0460
doi: 10.1089/dia.2016.0460
pubmed: 28556672
pmcid: 5563859
Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW, Exchange T1D (2016) Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 39(2):264–270. https://doi.org/10.2337/dc15-1498
doi: 10.2337/dc15-1498
pubmed: 26681725